Regenxbio Inc (NAS:RGNX)
$ 8.92 0.16 (1.83%) Market Cap: 440.86 Mil Enterprise Value: 228.13 Mil PE Ratio: 0 PB Ratio: 1.26 GF Score: 65/100

Q2 2022 Regenxbio Inc Earnings Call Transcript

Aug 03, 2022 / 08:30PM GMT
Release Date Price: $33.99 (+6.85%)
Operator

Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Second Quarter 2022 REGENXBIO Inc. Earnings Conference Call. (Operator Instructions). At this time, I would like to turn the conference over to Mr. Vit Vasista, Chief Financial Officer, REGENXBIO. Sir, please begin.

Vittal K. Vasista
REGENXBIO Inc. - Executive VP & CFO

Good afternoon, and thank you for joining us today. With us today are Ken Mills, REGENXBIO's President and Chief Executive Officer, and Dr. Steve Pakola, our Chief Medical Officer.

Earlier this afternoon, REGENXBIO released financial and operating results for the second quarter ended June 30, 2022. The press release reporting our financial results is available on our website at www.regenxbio.com.

Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot